TruthArchive.ai - Related Video Feed

I found something interesting for Elon and the Doge team regarding Medicare. In 2022, Medicare filled 85,000 prescriptions for Perfinidone at $8,000 each, totaling $680 million. At my cost-plus pharmacy, the same prescription is only $200. Filling all 85,000 prescriptions with me would only cost $17 million. Medicare is overpaying by $663 million annually because Pharmacy Benefits Managers (PBMs) get a percentage of the cost, incentivizing them to inflate prices. The easy solution is to cancel the PBM contracts and use actual costs. If you want to check if PBMs have been raising the cost of your medications, go to forestparkpharmacy.com and check our price to see how much you could save.

One breast cancer drug costs over $16,000 per bottle in America. The same drug, from the same factory and company, costs one sixth the price in Australia. In Sweden, the identical product costs one tenth the American price.

A businessman told the speaker that the same fat shot drug cost him $88 in London, but $1,300 in New York. He was stunned that the identical pill, made in the same plant by the same company, had such different prices. The speaker discussed this with drug company representatives. They argued for about half an hour, but ultimately the representative admitted there was no justification for the price difference.

The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

A regular Ford car costs $175,000, while in London, people are buying it for $10,000 every day, all day long. The FDA will do everything to support the executive order. It's transformative.

Speaker 0 argues that 100-year-old automotive technology is continually refined and that exhaust from modern cars is cleaner than the air entering the intake in many cities, due to catalytic converters, NOx converters (notably in diesels), computer-controlled fuel injection, and stop-start systems. He claims that there is no justification for restricting petrol cars and contrasts this with restrictions on electric vehicles (EVs). He contends that the EV push is not about encouraging people to switch to EVs for environmental reasons but about driving people out of internal combustion engine (ICE) cars. The EV zero-emission vehicle mandate, he says, forces automotive manufacturers to sell an ever-increasing proportion of EVs each year, and he asserts this will destroy, bankrupt, and reduce mass-manufacturing conglomerates such as Volkswagen, Audi Group, Ford, and others. He cites an example with Volkswagen and Audi: they are not allowed to sell the desired mix of petrol and diesel vehicles because they will be fined £15,000 per car if they fail to sell 28% as EVs. He claims they are already restricting petrol and diesel sales, and notes that this pressure is already in place for 2025. He argues that European carmakers cannot sell many EVs because European cars are more expensive than cheaper Chinese imports. He shifts to a broader geopolitical economic view, stating this is not a mere consumer issue but a plan arranged by global financiers, describing it as a one-two punch: you cannot sell petrol and diesel because of mandates, and your cars are uncompetitive with cheaper Chinese imports. He notes there are 180 Chinese EV makers, with only one or two currently profitable; trade press reports suggest that by the end of the decade, seven to nine of them will be profitable while the rest will have failed. From this, he infers that someone is willing to spend hundreds of billions of dollars to manufacture cars at a loss so they can be delivered to Europe at a loss in order to destroy Europe’s mass-manufacturing capability. He concludes that as a result, there will simply not be enough cars to go around, and ultimately, the mandates will be moot because there will be none available.

The President has initiated a complete restructuring of the international trading system with a fair and reciprocal plan. For too long other countries have damaged our defense industrial base and threatened our national security. Take Europe, for example. The US runs a $230 billion trade deficit with them, especially in the auto industry. A Cadillac faces tariffs and VAT taxes that significantly increase its price in Germany, while a BMW coming to the US gets rebates, allowing it to be sold much cheaper. This disparity explains why Germany sells us eight times more cars than we sell them. To address this, we're going to identify how countries are unfairly exploiting us through tariffs and non-monetary barriers. Then we will determine reciprocal tariffs to counteract this unfairness, ensuring fair treatment for America. This isn't a political issue, it's an American issue. We want jobs, factories, and a strong defense industrial base here at home so we can be safe, secure, and prosperous.

The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

A businessman told the speaker that the same fat shot drug cost him $88 in London but $1,300 in New York. The drugs were identical, made in the same plant by the same company. The speaker discussed this with a representative from the drug companies, who admitted there was no justification for the price difference.

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

American patients were subsidizing socialist healthcare systems in the European Union. The European Union is nastier than China, but they will come down a lot. The U.S. has all the cards because the EU treated the U.S. unfairly. The EU sells the U.S. 13 million cars, but the U.S. sells them none. The EU sells the U.S. their agricultural products, but they don't take U.S. products. Because of this unfairness, the EU will have to pay more for healthcare, and the U.S. will have to pay less.

One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

The speaker states that countries represented by the European Union will be told "that game is up." If they "get cute," they won't be able to sell cars into the United States anymore. The speaker claims that European unions and other countries gave drug companies a price, expecting America to pay the difference to cover a shortfall. The speaker says "that's what we did, but we're not doing it anymore."

The speaker states that countries represented by the European Union will be told "that game is up." If they "get cute," they won't be able to sell cars into the United States anymore. The speaker claims that European Union countries gave drug companies a price, expecting America to pay the difference to cover a shortfall. The speaker says "that's what we did, but we're not doing it anymore."

There is a scandal involving electric vehicles (EVs) and their claimed efficiency. Two Washington attorneys argue that the government is misleading the public by inflating the fuel efficiency of EVs. They claim that carmakers multiply the efficiency of EVs by a factor of 6.67, resulting in exaggerated numbers. Additionally, compliance credits are given based on these inflated scores, which can be traded for cash. Tesla alone has received billions of dollars in credits. The report highlights that this information is buried deep in the federal register and not widely known. The speaker praises the report as excellent.

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker highlights the significant price difference, noting one person paid a small amount for the same shot in the UK. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world, according to the speaker, who questions the reason for this disparity.

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker stated that an individual in the UK paid a small amount for their shot, contrasting sharply with the $500 cost in the US. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world. The speaker questions the reason for this disparity.

Big food, big pharma, big chemicals get super wealthy. Right? What is the product of health care? It's a healthy body. If we take The US population and compare it to the world, we're at the very bottom when it comes to health, yet we spend the most for health care. Over $4,100,000,000,000 every single year.

Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.

Reports from China indicate scientists may have found a diabetes cure, which is unwelcome news for the American pharmaceutical industry. Chinese patients receiving experimental stem cell therapy have stopped needing insulin after about eleven weeks. This poses a threat to companies like Eli Lilly, who profit greatly from the insulin market. The rising insulin prices have sparked controversy, especially considering insulin's inventor, Frederick Banting, sold the patent for $1, believing it should be accessible to everyone. A diabetes cure would reduce the demand for insulin, impacting pharmaceutical companies' profits. This reveals a contradiction within the American for-profit healthcare system, where cures are disincentivized if they eliminate the need for repeat customers, challenging the notion that capitalism always promotes innovation.

Healthcare companies will likely make the same amount of money because it's a redistribution of wealth across the world, not just the European Union. Europe and the rest of the world will pay a little more, while America will pay a lot less. This is due to America having a smaller population compared to the entire world. The top line for healthcare companies could remain the same, but it will be distributed differently.

The U.S. government, through the State Department, is apparently spending $400 million in taxpayer money on "armored Tesla production units." It raises questions about potential corruption and who benefits from this deal. This contract was not initiated during the Trump administration, but rather approved under Joe Biden.

Americans are programmed to trust only FDA-approved drugs, but Big Pharma buys the FDA's approval. The FDA stopped independently reviewing all drugs about 30 years ago. Drugmakers can pay a lump sum upfront, such as $10,000,000, to get immediate approval to sell their products. The approval is granted if the drugmaker believes and can prove through their own research studies that the drug is safe and effective.

Major drug companies are controlled by a group that includes representatives from Chase Manhattan Bank and Exxon. Their goal is to control all aspects of biology, from birth to death, including hormones, glands, and genes. John D. Rockefeller took over the medical industry in 1910, creating a monopoly that still exists today. This has led to skyrocketing healthcare costs, especially for cancer treatment, which can cost around $120,000. Despite the high costs, doctors often offer little hope for a cure. These monopolies are all connected and controlled by a small group of elitists known as the world order people.